Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Company Overview

Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies to treat diseases driven by gut microbial imbalance. Leveraging its proprietary Microbial Ecosystem Therapeutics (MET) platform, Finch engineers defined consortia of live microbes designed to restore healthy microbiome function. Its lead candidate, CP101, is in late-stage development for prevention of recurrent Clostridioides difficile infection (rCDI), and the company is advancing additional programs in inflammatory bowel disease, autism spectrum disorder and other immune-mediated conditions.

Founded in 2015 as an outgrowth of research at Massachusetts General Hospital and the Massachusetts Institute of Technology, Finch Therapeutics is headquartered in Cambridge, Massachusetts. The company has built in-house manufacturing capabilities through its SurePath platform, enabling scalable production of complex microbial therapies under stringent quality standards. Finch collaborates with academic centers and industry partners to accelerate clinical development and explore new therapeutic areas.

Under the leadership of co-founder and Chief Executive Officer Mark J. Smith, Finch has advanced multiple investigational products through early- and late-stage trials. The management team brings deep expertise in microbiology, clinical development and regulatory affairs, and is supported by a scientific advisory board of leading researchers in immunology, gastroenterology and microbial science. Finch’s clinical programs are primarily based in North America, with plans to initiate trials in additional regions as its pipeline progresses.

As a pioneer in the emerging field of microbiome therapeutics, Finch Therapeutics Group is dedicated to translating cutting-edge science into innovative treatments that address significant unmet medical needs. By harnessing the power of the human microbiome, Finch aims to deliver new therapeutic options that have the potential to transform the standard of care for patients suffering from chronic and recurrent diseases.

Key Stats

• Today's Range: $12.20 to $12.30
• 50-Day Range: $12.00 to $13.48
• 52-Week Range: $10.15 to $15.85
• Volume: 8,461 shs
• Average Volume: 2,274 shs
• Market Capitalization: $19.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FNCH Stock Analysis - Frequently Asked Questions

How have FNCH shares performed this year?

Finch Therapeutics Group's stock was trading at $11.30 at the beginning of 2025. Since then, FNCH stock has increased by 8.1% and is now trading at $12.2160.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($6.30) earnings per share for the quarter, topping the consensus estimate of ($12.60) by $6.30. The business earned $11.34 million during the quarter.

When did Finch Therapeutics Group's stock split?

Finch Therapeutics Group shares reverse split on Monday, June 12th 2023.The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Finch Therapeutics Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FNCH
• CIK: 1733257
• Web: www.finchtherapeutics.com
• Phone: 617-229-6499
• Fax: N/A
• Employees: 190
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($8.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.14%
• Return on Assets: -26.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.87
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.25 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 1,606,000
• Free Float: 885,000
• Market Cap: $19.62 million
• Optionable: No Data
• Beta: 1.20